TG Therapeutics shares made new 52-week highs this week, helped in part by new Briumvi data presentations at ECTRIMS. Find ...

Five years of continuous Briumvi kept MS relapse rates and disability progression low, according to analyses from a trial's ...

TG Therapeutics yesterday shared new five-year data from the ULTIMATE I & II Phase III trials evaluating Briumvi (ublituximab ...

TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of ...

The trials evaluated BRIUMVI (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS) over five years. The presentations highlighted the long-term efficacy and safety of BRIUMVI ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

NEW YORK - TG Therapeutics, Inc. (NASDAQ: NASDAQ:TGTX) has released updated data from its ENHANCE Phase 3b trial concerning BRIUMVI (ublituximab-xiiy), a treatment for relapsing forms of multiple ...

(RTTNews) - TG Therapeutics (TGTX) presented updated data from the ENHANCE Phase 3b trial evaluating BRIUMVI in patients with relapsing forms of multiple sclerosis. The company said the data ...

TG Therapeutics stock popped Wednesday after the company unveiled promising five-year test results for its multiple sclerosis ...

We recently compiled a list of the 14 Worst 52-Week High Stocks to Buy According to Short Sellers. In this article, we are ...

TG Therapeutics, Inc. (NASDAQ:TGTX) stock is trading higher on Wednesday after the company announced it updated its data ...

Its primary treatment option is BRIUMVI for the treatment of multiple sclerosis. While the stock is trading near its 52-week highs, the rally has resulted in the company delivering positive ...